Trade 73

SELL ORCL

0.430382388 shares at $213.07 on 2026-06-08

Reasoning

Execute playbook action #120. ORCL position is up ~10% from $191.48 cost (current ~$210.83 based on recent momentum). Binary earnings catalyst Wednesday June 10 (post-close, 2 trading days away) fits Rule #5 profit-take discipline: take 30% off to lock gains while retaining core upside to OCI backlog acceleration thesis. Sell-side raising PTs into print (TD Cowen Buy, Oppenheimer/Evercore Outperform) validates entry-into-print attractiveness but confirms binary nature. Not a reversal—consistent with mechanical de-risk-ahead-of-catalyst policy. Position remains exposed to positive earnings surprise with reduced downside risk.

Thesis

ORCL long — OCI/AI-compute structural thesis intact on fundamentals, but the AI-debt-scrutiny risk line has MATERIALLY SHARPENED on Oct 8. The FT reported OpenAI's annualized revenue is ~$50B at end-September, roughly $20B BELOW the ~$70B widely reported — a meaningful reset to the demand assumptions underpinning Oracle's ~$300B/5yr OpenAI compute contract (the single largest counterparty in Oracle's RPO backlog). ORCL fell ~5% on the news; NVDA/MSFT/AMD also lower. Simultaneously the long end is surging: the 30Y Treasury auction printed the highest yield since 2000 and the 30Y is nearing 6% — bond investors demanding higher yields on debt-heavy AI issuers is the live theme, and Oracle (Moody's negative outlook, debt toward 4x earnings on the buildout) is the most exposed held name to this exact channel. The combination of (a) a single-counterparty demand reset at Oracle's largest customer and (b) a fresh long-end spike is precisely the 'credit-market stress repricing AI-capex borrowers' invalidation condition. De-risk the position toward a smaller core; do not add. Note: the OpenAI figure is a calculation/accounting reset, not a revenue collapse — so this is a trim, not a full exit; the OCI-fundamentals invalidation (sub-25% YoY cloud growth, RPO shrinking) governs the remaining-core exit. (long, medium confidence)

Outcome

7-day: +12.36% · 30-day: +40.93%

Cited evidence

News

Macro